Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer

Inclusion Criteria: * Histologically or cytologically confirmed breast cancer * Local-regional recurrences or metastatic disease * At least 1 unidimensionally measurable lesion at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan * No history or evidence of CNS disease (e.g., primary brain tumor or any brain metastases) * Hormone receptor status: * Not specified * Female * Performance status - ECOG 0-2 * Performance status - Karnofsky 60-100% * More than 3 months * WBC at least 3,000/mm\^3 * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * No bleeding diathesis or coagulopathy * Bilirubin normal * AST/ALT no greater than 2.5 times upper limit of normal * INR less than 1.5 (patients receiving warfarin) * Creatinine normal * Creatinine clearance at least 60 mL/min * No baseline proteinuria * Patients with proteinuria of 1+ or greater at baseline are allowed provided 24-hour urinary protein is less than 500 mg * No symptomatic congestive heart failure * No cardiac arrhythmia * No uncontrolled hypertension * No history of stroke * No clinically significant peripheral artery disease * No arterial thromboembolic event within the past 6 months, including any of the following: * Transient ischemic attack * Cerebrovascular accident * Unstable angina * Myocardial infarction * HIV negative * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No seizures not controlled with standard medical therapy * No prior allergic reactions attributed to compounds of similar chemical or biological composition to study agents * No psychiatric illness or social situation that would preclude study compliance * No ongoing or active infection * No other concurrent uncontrolled illness * No non-healing wounds * No significant traumatic injury within the past 28 days * Prior adjuvant chemotherapy allowed (up to 1 regimen for metastatic disease) * More than 6 months since prior taxane-containing adjuvant chemotherapy * More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered * More than 3 weeks since prior radiotherapy * More than 28 days since prior major surgery or open biopsy * More than 7 days since prior fine needle aspirations other than in the breast * More than 7 days since prior placement of a vascular access device * No concurrent major surgical procedure * No concurrent or recent full-dose oral or parenteral anticoagulants or thrombolytic agents (except as required to maintain patency of preexisting, permanent indwelling IV catheters) * No other concurrent investigational agents * No concurrent chronic daily aspirin (more than 325 mg/day) or nonsteroidal anti-inflammatory medications (known to inhibit platelet function at doses used to treat chronic inflammatory diseases)